Heart failure and inhibition of renin-angiotensin-aldosterone system

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F18%3A00068641" target="_blank" >RIV/00159816:_____/18:00068641 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/18:00103230 RIV/65269705:_____/18:00068641
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0010865018300055?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0010865018300055?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.crvasa.2018.02.003" target="_blank" >10.1016/j.crvasa.2018.02.003</a>

Result language
angličtina
Original language name
Heart failure and inhibition of renin-angiotensin-aldosterone system
Original language description
A historical survey is presented of mortality clinical trials focussed on the inhibition of the renin-angiotensin-aldosterone system on different levels in patients with chronic heart failure. The first study, CONSENSUS, was published in 1987 and showed that the ACE-inhibitor enalapril clearly reduced mortality in severe heart failure compared with placebo. This was followed by studies with beta blockers, angiotensin II type 1 receptor blockers, blockers of mineralocorticoid receptors, and direct renin inhibitors. A recent study, PARADIGM, comparing dual inhibitor of neprilysin and antiotensin II receptor (LCZ 696) with enalapril, was terminated prematurely for a significant effect of inhibiting neprilysin and valsartan.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)